SV

Street Verdict

Analyst Scorecard

NEULANDLAB · NSE

Neuland Laboratories Limited

₹20,642

-2.18% (-₹460)

Prev. close

₹21,102

Volume

37,328

Delivery %

51.2%

As of

20 Nov 2026

Price history

₹20,642-₹2,728 (-11.67%) · 3M
18 Aug 2026 → 20 Nov 2026
19,00020,00021,00022,00023,00018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Long-Horizon calls · 1yr+ horizon · verdict pending

CallAnalystInstrumentVerdictActions

Fundamentals

About Neuland Laboratories Limited

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Davuluri Saharsh Rao

Headquarters

Hyderabad

Employees

2,183

Key stats

Market cap

₹25,115.79 Cr

P/E ratio (TTM)

55.5

Dividend yield

0.18%

EPS (TTM)

₹352.72

Beta (1Y · daily vs NIFTY 50)

0.85

Beta (5Y · monthly vs NIFTY 50)

1.36

Shares float

73.55 L

EPS · quarter ended Jun 2026

₹115.10

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%5%10%15%20%FY21FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0100200300₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

010203040₹-50%0%50%100%18 Feb 2010 Nov 2029 Jun 2114 Jul 2211 Jul 2312 Jul 2418 Jul 2524 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.25×0.5×0.75×1×FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-200 Cr0 Cr200 Cr400 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹936.91 Cr₹951.08 Cr₹1,191.20 Cr₹1,558.58 Cr₹1,476.84 Cr₹2,022.99 Cr
EBITDA
₹162.91 Cr₹144.70 Cr₹281.59 Cr₹475.13 Cr₹420.17 Cr₹604.66 Cr
₹80.63 Cr₹63.82 Cr₹163.52 Cr₹300.08 Cr₹260.11 Cr₹364.00 Cr
Diluted EPS
₹62.85₹49.74₹127.45₹233.89₹202.74₹283.71

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
—₹1,383.49 Cr₹1,579.76 Cr₹1,832.56 Cr₹2,179.88 Cr₹2,930.14 Cr
—₹240.53 Cr₹128.45 Cr₹95.39 Cr₹157.14 Cr₹301.27 Cr
Stockholders' equity
—₹840.50 Cr₹994.10 Cr₹1,282.70 Cr₹1,524.81 Cr₹1,874.47 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹189.36 Cr₹58.58 Cr₹237.21 Cr₹261.18 Cr₹317.38 Cr₹346.68 Cr
Investing cash flow
₹-84.42 Cr₹-93.71 Cr₹-61.50 Cr₹-149.69 Cr₹-298.16 Cr₹-423.73 Cr
₹-113.66 Cr₹37.72 Cr₹-135.80 Cr₹-69.28 Cr₹24.96 Cr₹20.98 Cr
Capital expenditure
₹-105.40 Cr₹-96.89 Cr₹-66.13 Cr₹-143.67 Cr₹-206.46 Cr₹-397.13 Cr
End cash position
—₹5.09 Cr₹45.42 Cr₹87.58 Cr₹131.93 Cr₹76.67 Cr

Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Sep 22(5Q)Dec 22–Mar 23(2Q)Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24–Jun 25(3Q)Sep 25Dec 25–Mar 26(2Q)Jun 26
Promoter36.22%36.14%36.03%35.97%32.80%32.74%32.72%32.64%32.68%32.64%32.63%32.62%
Public63.78%63.86%63.97%64.03%67.20%67.26%67.28%67.36%67.32%67.36%67.37%67.38%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Neuland Laboratories Limited₹24,920.78 Cr₹19,57650.113.2919.4%0.16+34.7%+11.2%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

NEULANDLAB

Neuland Laboratories falls 2.85% in Friday's session

Global Banking & Finance Review · 2 days ago

NEULANDLAB

Neuland Laboratories September profit falls 47% on sales decline

Multibagg AI · 18 days ago